Chronos Archive seal
The Human Record

Mahalia Jackson

Case HR-ML035 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
October 26, 1911 – January 27, 1972
Synthetic DOB
1973-10-26
Index visit
2026-02-09 at age 52
Synthetic MRN
HR-ML035-SYN

Teaching objective: Diagnose and treat sarcoidosis with cardiac involvement in a 52-year-old Black woman and touring singer, in whom sarcoidosis is more common and more often severe and fatal than in White Americans, on the ATS 2020 diagnosis guideline, the ERS 2021 treatment guideline, the HRS 2014 cardiac sarcoidosis consensus and the AHA 2024 scientific statement: chest imaging with bilateral hilar adenopathy; pulmonary function with DLCO; EBUS-guided lymph node aspiration showing non-necrotizing granulomas, with tuberculosis and fungal infection excluded; screening every patient for other organ involvement (eye examination, ECG, calcium and vitamin D handling, liver and kidney tests); cardiac evaluation with ECG, Holter monitoring, echocardiography, cardiac MRI and FDG-PET before treatment begins; prednisone with methotrexate as a steroid-sparing agent, with methotrexate safety monitoring; bone protection that avoids calcium supplements while calcium is high; pneumocystis prophylaxis, vaccination and tuberculosis screening before immunosuppression; arrhythmia risk stratification with electrophysiology study and a defibrillator; and a plan that protects her voice, her performing and her travel.

Historical timeline

DateEventClaims
October 26, 1911Born in New Orleans.CLM-0001
1928Moves to Chicago and joins the Greater Salem Baptist Church.CLM-0002
October 4, 1950Carnegie Hall debut.CLM-0002, CLM-0004
1952First European tour, sung in pain with breathlessness, then cancelled; hysterectomy, with granulomas found and sarcoidosis diagnosed.CLM-0005
August 28, 1963Sings at the March on Washington.CLM-0003
1964 to 1965Admitted in Chicago after a coughing spell (month not recorded); told privately of a heart attack and sarcoidosis in her heart; a year of recovery without touring.CLM-0006, CLM-0012
Fall 1967Hospitalized for heart trouble.CLM-0007
1968Cuts short a European tour; eye inflammation and cramps in her legs and hands.CLM-0008
1971Tours Japan, India and Europe; falls ill in Germany after her last concert, in Munich, and is hospitalized at home.CLM-0009
January 27, 1972Dies at Little Company of Mary Hospital in Evergreen Park, Illinois, at 60.CLM-0010, CLM-0011

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Mahalia Jackson was born in New Orleans on October 26, 1911, the third of six children of a man who was a longshoreman by day, a barber by night and a clergyman on Sunday. Her mother died when she was six, and she was raised by an aunt in a poor but respectable home; she left school in the eighth grade to work as a cook and washerwoman. confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
HISTMED Master Roster v3 context
D In 1928 she moved to Chicago, worked as a hotel maid and laundress, and joined the Greater Salem Baptist Church, where she became a soloist. She never learned to read music. After her Carnegie Hall debut on October 4, 1950, she began touring abroad in 1952, and toured widely for the rest of her life.
Her life as a touring singer anchors the modern social history and the plan built around her performing and travel.
confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
Mahalia Jackson (This Far by Faith) supports
D She was closely associated with the civil rights movement and sang at the March on Washington in 1963 before Dr. Martin Luther King Jr.'s speech. When she moved into an all-white neighborhood on the South Side of Chicago, a bullet was fired through a window of her home.
Anchors the modern social history: a singer whose work was bound up with the civil rights movement, who met racist violence at home.
confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
D Touring the segregated South for as many as 200 dates a year, she and her company had trouble finding safe places to sleep, eat and buy gas, sometimes slept in her car, lived on bags of fruit and drove half the night, and she arrived so exhausted she was almost dizzy when she sang; she insisted on being paid in cash because checks were often refused.
Context for the modern social history; the details come from a tertiary summary of her autobiography and Goreau's biography.
probable Mahalia Jackson supports
Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports
D Before and during her first European tour in 1952 she had difficulty breathing during and after performances and severe abdominal cramping, sang many shows in pain, lost a great deal of weight and finally cancelled the tour. On her return she had a hysterectomy, at which numerous granulomas were found in her abdomen, and she was diagnosed with sarcoidosis. From then on she had occasional bouts of fatigue and shortness of breath that became more frequent as her schedule filled.
The anchor for the modern presenting problem and the past history. The account rests on Goreau's biography as summarized by Wikipedia and on TheWrap; no pathology record was found.
probable Mahalia Jackson supports
Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports
D In 1964, weeks after her marriage, she could not stop coughing on the drive home from a concert in St. Louis and admitted herself to a Chicago hospital. The diagnosis given in public was heart strain and exhaustion; her doctors told her privately that she had had a heart attack and that sarcoidosis was now in her heart. Recovery took a year, during which she could not tour or record and lost about 50 pounds; afterwards she had near-constant fatigue, bouts of tachycardia and high blood pressure. From 1964 she was in and out of hospitals, and physicians warned her of exhaustion from her itineraries.
The documented cardiac illness to which the modern diagnosis of cardiac sarcoidosis is linked. The account of what her doctors told her privately comes from Goreau's biography as summarized by Wikipedia.
probable Mahalia Jackson supports
Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports
D She was hospitalized for heart trouble in the fall of 1967.
Documented heart illness after the index date.
confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
D By the late 1960s she had inflammation in her eyes and painful cramps in her legs and hands; she cut short a European tour in 1968 for health reasons.
Documented symptoms after the index date; that the eye inflammation was sarcoid uveitis is not stated in the sources.
probable Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports
Mahalia Jackson supports
D In 1971 she toured Japan, India and Europe; she became ill on tour in Germany, where she gave her last concert in Munich, and was flown home to Chicago and hospitalized in the fall.
Documented final illness; history only.
confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
Mahalia Jackson supports
Mahalia Jackson Theater for the Performing Arts supports
Mahalia Jackson supports
D She died on January 27, 1972, at Little Company of Mary Hospital in Evergreen Park, Illinois, at 60, after several years of poor health.
The documented death. History only, stated without detail.
confirmed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
Nixon R. Statement on the Death of Mahalia Jackson (January 27, 1972) supports
R The cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap).
Retrospective; the accounts conflict, and none gives a medical record. The modern episode does not resolve the question.
disputed Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports
Mahalia Jackson (This Far by Faith) supports
Mahalia Jackson supports
Mahalia Jackson Theater for the Performing Arts supports
Mahalia Jackson supports
Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports
R That her heart disease, and the heart trouble that recurred until her death, was cardiac sarcoidosis is a retrospective interpretation. It rests on the private account of her doctors in 1964 reported by her biographer; the public diagnoses were heart strain, exhaustion and heart trouble.
Retrospective interpretation linked to the modern cardiac sarcoidosis problem; it is not a confirmed historical diagnosis.
possible Mahalia Jackson supports
Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) context

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded resolved confirmed active CLM-0005
S Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for resolved confirmed active CLM-0005
S Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised resolved confirmed active CLM-0005
S Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis active confirmed both_with_link CLM-0005, CLM-0006
S Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolved resolved confirmed active
S Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart active confirmed both_with_link CLM-0006, CLM-0012
S Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage active confirmed active
S Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring active confirmed active CLM-0006, CLM-0012

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-09 Hemoglobin [Mass/volume] in Blood 12.4 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-02-09 Leukocytes [#/volume] in Blood by Automated count 4.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-02-09 Lymphocytes [#/volume] in Blood by Automated count 0.9 10*3/uL (low)
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-02-09 Platelets [#/volume] in Blood by Automated count 232 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-02-09 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-02-09 Potassium [Moles/volume] in Serum or Plasma 4.1 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-02-09 Creatinine [Mass/volume] in Serum or Plasma 1.08 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-02-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 62 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-09 Glucose [Mass/volume] in Serum or Plasma 104 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-09 Calcium [Mass/volume] in Serum or Plasma 10.8 mg/dL (high)
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-02-09 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-02-09 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-02-09 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 128 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-02-09 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-02-09 Hemoglobin A1c/Hemoglobin.total in Blood 5.9% (high)
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes
http://loinc.org · 4548-4
S 2026-02-09 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 22 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-02-09 1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma 84 pg/mL (high)
Reference 18-72 pg/mL
http://loinc.org · 62290-2
S 2026-02-09 Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 210 pg/mL (high)
Reference <=125 pg/mL
http://loinc.org · 33762-6
S 2026-02-09 Thyrotropin [Units/volume] in Serum or Plasma 1.8 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-02-09 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-02-23 FVC measured/predicted 74% (low)
Reference >=80%
http://loinc.org · 19872-1
S 2026-02-23 FEV1 measured/predicted 76% (low)
Reference >=80%
http://loinc.org · 20152-5
S 2026-02-23 FEV1/FVC 80%
Reference >=70%
http://loinc.org · 19926-5
S 2026-02-23 Diffusion capacity.carbon monoxide/Predicted 62% (low)
Reference >=80%
http://loinc.org · 98130-8
S 2026-02-23 Calcium [Mass/volume] in Serum or Plasma 10.7 mg/dL (high)
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-02-23 Creatinine [Mass/volume] in Serum or Plasma 1.04 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-02-23 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 65 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-23 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-03-09 Hemoglobin [Mass/volume] in Blood 12.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-03-09 Leukocytes [#/volume] in Blood by Automated count 4.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-03-09 Lymphocytes [#/volume] in Blood by Automated count 0.9 10*3/uL (low)
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-03-09 Platelets [#/volume] in Blood by Automated count 240 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-03-09 Creatinine [Mass/volume] in Serum or Plasma 1.02 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-03-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 66 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-09 Glucose [Mass/volume] in Serum or Plasma 101 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-09 Calcium [Mass/volume] in Serum or Plasma 10.6 mg/dL (high)
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-03-09 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-03-09 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-03-09 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 124 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-03-09 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-03-09 Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 240 pg/mL (high)
Reference <=125 pg/mL
http://loinc.org · 33762-6
S 2026-03-09 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-05-11 Hemoglobin [Mass/volume] in Blood 13.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-05-11 Leukocytes [#/volume] in Blood by Automated count 9.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-05-11 Lymphocytes [#/volume] in Blood by Automated count 1.2 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-05-11 Platelets [#/volume] in Blood by Automated count 262 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-05-11 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-05-11 Potassium [Moles/volume] in Serum or Plasma 3.9 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-05-11 Creatinine [Mass/volume] in Serum or Plasma 0.92 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-05-11 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 75 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-11 Glucose [Mass/volume] in Serum or Plasma 118 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-05-11 Calcium [Mass/volume] in Serum or Plasma 9.6 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-05-11 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-05-11 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-05-11 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 U/L
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-05-11 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-05-11 Hemoglobin A1c/Hemoglobin.total in Blood 6.3% (high)
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes
http://loinc.org · 4548-4
S 2026-05-11 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 24 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-05-11 Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 140 pg/mL (high)
Reference <=125 pg/mL
http://loinc.org · 33762-6
S 2026-05-11 FVC measured/predicted 84%
Reference >=80%
http://loinc.org · 19872-1
S 2026-05-11 FEV1 measured/predicted 85%
Reference >=80%
http://loinc.org · 20152-5
S 2026-05-11 FEV1/FVC 80%
Reference >=70%
http://loinc.org · 19926-5
S 2026-05-11 Diffusion capacity.carbon monoxide/Predicted 70% (low)
Reference >=80%
http://loinc.org · 98130-8
S 2026-05-11 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-08-24 Hemoglobin [Mass/volume] in Blood 13 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-08-24 Leukocytes [#/volume] in Blood by Automated count 8.1 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-08-24 Lymphocytes [#/volume] in Blood by Automated count 1.4 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-08-24 Platelets [#/volume] in Blood by Automated count 248 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-08-24 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-08-24 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 77 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-08-24 Glucose [Mass/volume] in Serum or Plasma 108 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-08-24 Calcium [Mass/volume] in Serum or Plasma 9.5 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-08-24 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-08-24 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-08-24 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 90 U/L
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-08-24 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-08-24 Hemoglobin A1c/Hemoglobin.total in Blood 6.2% (high)
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes
http://loinc.org · 4548-4
S 2026-08-24 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-08-24 Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 96 pg/mL
Reference <=125 pg/mL
http://loinc.org · 33762-6
S 2026-08-24 FVC measured/predicted 90%
Reference >=80%
http://loinc.org · 19872-1
S 2026-08-24 FEV1 measured/predicted 89%
Reference >=80%
http://loinc.org · 20152-5
S 2026-08-24 FEV1/FVC 79%
Reference >=70%
http://loinc.org · 19926-5
S 2026-08-24 Diffusion capacity.carbon monoxide/Predicted 76% (low)
Reference >=80%
http://loinc.org · 98130-8
S 2026-08-24 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-10-05 Cholesterol [Mass/volume] in Serum or Plasma 204 mg/dL (high)
Reference <=200 mg/dL
http://loinc.org · 2093-3
S 2026-10-05 Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-10-05 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 126 mg/dL
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 2026-10-05 Triglyceride [Mass/volume] in Serum or Plasma 118 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-10-05 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-09Body height170 cm8302-2S
2026-02-09Body weight92 kg29463-7S
2026-02-09Body mass index (BMI) [Ratio]31.8 kg/m239156-5S
2026-02-09Systolic blood pressure128 mm[Hg]8480-6S
2026-02-09Diastolic blood pressure80 mm[Hg]8462-4S
2026-02-09Heart rate86 /min8867-4S
2026-02-09Respiratory rate18 /min9279-1S
2026-02-09Body temperature36.8 Cel8310-5S
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry95 %59408-5S
2026-02-23Body height170 cm8302-2S
2026-02-23Body weight91.6 kg29463-7S
2026-02-23Body mass index (BMI) [Ratio]31.7 kg/m239156-5S
2026-02-23Systolic blood pressure126 mm[Hg]8480-6S
2026-02-23Diastolic blood pressure78 mm[Hg]8462-4S
2026-02-23Heart rate82 /min8867-4S
2026-02-23Respiratory rate18 /min9279-1S
2026-02-23Body temperature36.7 Cel8310-5S
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry95 %59408-5S
2026-03-09Body height170 cm8302-2S
2026-03-09Body weight91.2 kg29463-7S
2026-03-09Body mass index (BMI) [Ratio]31.6 kg/m239156-5S
2026-03-09Systolic blood pressure124 mm[Hg]8480-6S
2026-03-09Diastolic blood pressure78 mm[Hg]8462-4S
2026-03-09Heart rate80 /min8867-4S
2026-03-09Respiratory rate18 /min9279-1S
2026-03-09Body temperature36.6 Cel8310-5S
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry95 %59408-5S
2026-05-11Body height170 cm8302-2S
2026-05-11Body weight94 kg29463-7S
2026-05-11Body mass index (BMI) [Ratio]32.5 kg/m239156-5S
2026-05-11Systolic blood pressure138 mm[Hg]8480-6S
2026-05-11Diastolic blood pressure86 mm[Hg]8462-4S
2026-05-11Heart rate66 /min8867-4S
2026-05-11Respiratory rate16 /min9279-1S
2026-05-11Body temperature36.6 Cel8310-5S
2026-05-11Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-08-24Body height170 cm8302-2S
2026-08-24Body weight93 kg29463-7S
2026-08-24Body mass index (BMI) [Ratio]32.2 kg/m239156-5S
2026-08-24Systolic blood pressure130 mm[Hg]8480-6S
2026-08-24Diastolic blood pressure82 mm[Hg]8462-4S
2026-08-24Heart rate64 /min8867-4S
2026-08-24Respiratory rate16 /min9279-1S
2026-08-24Body temperature36.7 Cel8310-5S
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-06-15Body height170 cm8302-2S
2026-06-15Body weight93.4 kg29463-7S
2026-06-15Body mass index (BMI) [Ratio]32.3 kg/m239156-5S
2026-06-15Systolic blood pressure134 mm[Hg]8480-6S
2026-06-15Diastolic blood pressure84 mm[Hg]8462-4S
2026-06-15Heart rate72 /min8867-4S
2026-06-15Respiratory rate16 /min9279-1S
2026-06-15Body temperature37.4 Cel8310-5S
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-10-05Body height170 cm8302-2S
2026-10-05Body weight92.2 kg29463-7S
2026-10-05Body mass index (BMI) [Ratio]31.9 kg/m239156-5S
2026-10-05Systolic blood pressure128 mm[Hg]8480-6S
2026-10-05Diastolic blood pressure80 mm[Hg]8462-4S
2026-10-05Heart rate66 /min8867-4S
2026-10-05Respiratory rate16 /min9279-1S
2026-10-05Body temperature36.7 Cel8310-5S
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation2026-03-09completedEBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks
Calcium in the normal range within three months2026-05-11completedCalcium 9.6 mg/dL after nine weeks of treatment
FVC and DLCO improved by at least 10 percent of predicted within six months2026-08-24completedFVC 74 to 90 percent and DLCO 62 to 76 percent of predicted
No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better2026-08-24completedMyocardial uptake resolved; ejection fraction 54 percent from 47
Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent2026-08-24completedPrednisone 10 mg at six months and tapering
Back on stage with a schedule she can sustain, with her voice protected2026-08-24completedTwo concerts a week since late spring; a longer autumn tour planned

Interventions

InterventionStatusGuideline
Pulmonology (sarcoidosis) consultation within two weeks, with EBUS-guided lymph node sampling arranged directly from the referral, to confirm the diagnosis and plan treatmentcompletedGL-ATS-SARC-2020, GL-ERS-SARC-2021
Diagnosis of suspected sarcoidosis: chest radiograph and CT of the chest, tissue by EBUS-guided needle aspiration rather than mediastinoscopy, stains and cultures for mycobacteria and fungi, an interferon-gamma release assay and HIV test to exclude other causes; serum ACE is not used to make or exclude the diagnosiscompletedGL-ATS-SARC-2020
Screening every patient with suspected sarcoidosis for other organ involvement: ECG, serum calcium with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, creatinine, liver tests and alkaline phosphatase, complete blood count, TSH, and an eye examination; stop the calcium and vitamin D supplement while calcium is highcompletedGL-ATS-SARC-2020
Cardiac evaluation for suspected cardiac sarcoidosis (abnormal ECG and palpitations): 24-hour Holter monitoring, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with a dietary preparation, all before glucocorticoids begin; cardiology and electrophysiology reviewcompletedGL-HRS-CS-2014, GL-AHA-CS-2024, GL-ATS-SARC-2020
Treatment of cardiac and pulmonary sarcoidosis: prednisone 40 mg daily, tapered over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly (increased to 20 mg) and folic acid, continued for at least a year for cardiac disease; repeat FDG-PET after about six monthscompletedGL-ERS-SARC-2021, GL-AHA-CS-2024, GL-HRS-CS-2014
Methotrexate safety: hepatitis B and C screening before starting, blood count, liver tests and creatinine every two to four weeks for the first three months and then every eight to twelve weeks, no alcohol, and no trimethoprim-sulfamethoxazole while on methotrexatecompletedGL-ACR-DMARD-2012, GL-ERS-SARC-2021
Glucocorticoid protection: bone density scan and FRAX, alendronate weekly, dietary calcium only (no supplements while calcium was high), vitamin D replaced cautiously once calcium is normal, with calcium rechecked; atovaquone pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate; glucose, blood pressure, weight, mood, sleep and eye pressure checkscompletedGL-ACR-GIOP-2022, GL-CMID-2026, GL-ERS-SARC-2021
Vaccination before immunosuppression: PCV20, recombinant zoster vaccine, hepatitis B vaccine for a non-immune adult, influenza and COVID-19 vaccines; no live vaccines while on prednisone and methotrexatecompletedGL-CDC-IMZ-2026
Arrhythmia risk: metoprolol for ventricular ectopy; electrophysiology study for a left ventricular ejection fraction above 35 percent with scar on MRI and nonsustained ventricular tachycardia, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced; remote device monitoring, including on tourcompletedGL-HRS-CS-2014, GL-AHA-CS-2024
Performing and travel: concerts paused until the defibrillator wound has healed and the first device check is done, then a lighter schedule with rest days, voice care, and a travel letter with her device card and medicine list; no driving for one week after the implantcompletedGL-HRS-CS-2014, GL-ERS-SARC-2021
Depression screening at each phase, plain explanations with written information, and support she chooses; she decides who receives each notecompletedGL-USPSTF-DEP-2023

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) The New York Times (On This Day archive) other
SRC-0002 Nixon R. Statement on the Death of Mahalia Jackson (January 27, 1972) The American Presidency Project, University of California, Santa Barbara other
SRC-0003 Mahalia Jackson (This Far by Faith) PBS other
SRC-0004 Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed TheWrap other
SRC-0005 Mahalia Jackson Wikipedia other
SRC-0006 Mahalia Jackson Biography.com (A&E Television Networks) other
SRC-0007 HISTMED Master Roster v3 The Human Record project other
SRC-0008 Mahalia Jackson Theater for the Performing Arts New Orleans Historical (University of New Orleans) other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the diagnosis by EBUS with infection excluded, the decision to complete cardiac MRI and FDG-PET before glucocorticoids, the prednisone dose and taper with methotrexate, the defibrillator decision after an inducible electrophysiology study with an ejection fraction of 47 percent, the handling of calcium and vitamin D with alendronate, atovaquone instead of trimethoprim-sulfamethoxazole with methotrexate, and the touring plan.
provenance reviewnot_startedShe died in 1972; the recent-death rule does not apply. Claims rest on The New York Times obituary, the presidential statement, PBS, Biography.com, New Orleans Historical, TheWrap and Wikipedia's summary of Goreau's biography. The cause of death and the cardiac sarcoidosis interpretation are R; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Weight is recorded as measured, without comment on her body. Her death is recorded once, without detail. No relative, spouse, colleague or historical physician is given a role in the modern episode.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.